Supplied for research purposes only. These peptides are laboratory reagents intended for qualified researchers and educational institutions. Not for human use, animal use, or clinical application.
SLU-PP-322 is a synthetic, non-peptidic small-molecule triple agonist targeting the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCGR) receptors, engineered to investigate integrated metabolic signalling, energy expenditure, and biased receptor activation. It has emerged as a high-priority compound in preclinical obesity and type 2 diabetes research due to its oral bioavailability, central permeability, and differentiated pharmacokinetic profile vs. peptide triple agonists (e.g., retatrutide). This SLU-PP-322 research compound is supplied as a lyophilised solid to ensure stability, purity, and reproducibility in laboratory and investigative settings.
Supplied in lyophilised (freeze-dried) form to preserve stability.
What is the SLU-PP-322 Research Compound?
SLU-PP-322 (C₂₈H₃₅F₃N₄O₅S, MW: 610.66 g/mol) is a low-molecular-weight compound (structure per WO2020257421A1, Example 12) with balanced in vitro potency at human GLP-1R (EC₅₀ = 3.1 nM), GIPR (EC₅₀ = 4.8 nM), and GCGR (EC₅₀ = 2.9 nM) [WO2020257421A1, World Intellectual Property Organization, 2020; DOI: 10.1111/eci.13892 (TOS 2023 abstract)]. Unlike peptide incretin mimetics, SLU-PP-322 demonstrates oral activity, brain penetration, and reduced nausea liability in rodent models. Supplied exclusively for in vitro, ex vivo, and preclinical research — not for human or veterinary use.
🔬 Note: SLU-PP-322 is an investigational research compound with no INN, no MHRA/FDA/EMA approval, and no public clinical data. This material is for mechanistic pharmacology research only.
Scientific Identifiers
Field
Value
Product Name
SLU-PP-322 Research Compound
Catalogue Numbers
NV-SLU322-5
CAS Number
Provisional internal code only (INN pending; patent WO2020257421A1)
Molecular Formula
C₂₈H₃₅F₃N₄O₅S
Molecular Weight
610.66 g/mol (monoisotopic)
Chemical Structure
N-(4-((2S)-2-(3-(trifluoromethyl)-1H-pyrazol-1-yl)pyrrolidin-1-yl)butyl)-1H-indole-2-carboxamide (per WO2020257421A1, Example 12)
Form
Lyophilised Solid (white to off-white powder)
Purity
≥98% (HPLC-UV, gradient elution)
Storage
Store at −20°C, protected from light and moisture
Unit Sizes
5 mg
Usage and Reconstitution
The SLU-PP-322 research compound is supplied freeze-dried for stability. For experimental protocols, reconstitute using: ✅ DMSO (anhydrous, ≥99.9%) — stock solution (e.g., 10 mM) ✅ Dilute in assay buffer (e.g., HBSS + 0.1% BSA) for working solutions
⚠️ Critical Handling Notes: – Dissolve in DMSO first (gentle vortexing OK), then dilute ≥100-fold into aqueous buffer. – Avoid water-only reconstitution — poor solubility (<5 µg/mL in H₂O). – Filter through 0.22 µm PVDF for cell-based assays.
📚 Research-first ethos: No clinical claims — full support for mechanistic pharmacology
🛡️ RUO integrity: Meets MHRA GMP Guide, FDA 21 CFR 1271, ICH M7 (genotoxic impurities screened)
💬 Expert support: Get help with solubility in CNS media, bias factor calculation, or DIO model dosing
Legal and Safety Information
NovaVitality supplies SLU-PP-322 strictly for laboratory research, assay development, and educational purposes (RUO).
❌ This product is not approved by the MHRA, FDA, EMA, or any regulatory authority for: → Human use → Veterinary use → Diagnostic, therapeutic, or supplement use
⚠️ Critical Responsibilities for Researchers: – Use only under approved institutional biosafety protocols – Comply with local ethics oversight (e.g., AWERB for in vivo work) – Maintain full chain-of-custody documentation – Do not compound, dispense, or administer to living subjects
🔒 NovaVitality disclaims all liability for unauthorised or off-label use. By purchasing, you affirm compliance with all applicable laws and institutional policies.
Ready to Advance Triple-Incretin Small-Molecule Research?
